<DOC>
	<DOCNO>NCT02151656</DOCNO>
	<brief_summary>The purpose study evaluate potential efficacy oral F17464 comparison placebo 6 week patient acute exacerbation schizophrenia . Study design : double-blind , randomize , placebo-controlled , parallel-groups , fixed-dose design , multicentre study .</brief_summary>
	<brief_title>F17464 Acute Schizophrenia Trial</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Demographic characteristic Male female , 1864 year age inclusive primary diagnosis schizophrenia undergo acute exacerbation prominent `` active phase '' symptom , describe Diagnostic Statistical Manual Mental Disorders , 4th edition Text Revision ( DSM IVTR ) use MINI 6.0 ( MiniInternational Neuropsychiatric Interview ) schizophrenia psychotic disorder relate DSM IVTR Welldocumented diagnosis schizophrenia minimum 1 year screen visit Since diagnosis schizophrenia , average number hospitalisation higher 2 per year ( minimum duration hospitalization 4 day ) During year Visit 1 , maximum 3 acute psychotic episode require hospitalization change antipsychotic medication therapeutic intervention Adequate clinical response wellconducted treatment course previous acute episode . A well conduct treatment course define antipsychotic treatment usual dose least 4 week Current acute episode Structured Clinical Interview Positive And Negative Syndrome Scale ( SCIPANSS ) PANSS total score ≥ 70 &lt; 120 ( Visit 1 2 ) Rating least 4 ( moderate ) least 2 follow 4 PANSS positive symptom : delusion , hallucinatory behaviour , conceptual disorganization , suspiciousness/persecution Clinical Global Impression Severity ( CGIS ) score ≥ 4 ( moderate severe ) Antipsychotic initiate acute episode and/or ongoing chronic antipsychotic treatment , maximum 2 antipsychotic total need change ( due inefficacy safety reason ) Hospitalization and/ treatment current psychotic episode less 2 week prior Visit 1 No significant improvement PANSS total score enrolment ( Visit 1 ) inclusion ( Visit 2 ) correspond score improvement &lt; 20 % positive symptom subscale Related pathology Patients first acute episode psychosis Current schizophrenic episode predominant negative symptom Patient `` know refractory `` define lack significant improvement ( significant relief symptom , period good function ) despite adequate course least 3 different antipsychotic medication cycle adequate duration ( least 4 week ) adequate dosage previous 5 year ; Schizoaffective disorder , schizophreniform disorder psychotic disorder ; Bipolar I II disorder Pervasive developmental disorder , mental retardation , delirium , dementia , memory impairment cognitive disorder would compromise reliable assessment accord investigator 's opinion Known suspect borderline antisocial personality disorder DSM IV axis II disorder sufficient severity interfere participation study History tardive dyskinesia chronic extrapyramidal symptom ( EPS ) , serotonin syndrome neuroleptic malignant syndrome Major depressive disorder require pharmacological treatment At imminent risk injure him/herself others cause significant damage property , judge investigator Suicidal risk base ColumbiaSuicide Severity Rating Scale ( CSSRS ) Any suicidal behavior past year Suicidal ideation type 4 5 past month Related treatment Structured psychotherapy ( e.g . cognitive behavioural therapy ) start within 6 week visit 1 Electroconvulsive therapy within 3 month Visit 1 Previous lack response electroconvulsive therapy Treatment ongoing depot neuroleptic ( even less 1 cycle duration Visit 1 ) Patient previous treatment course clozapine within 4 month prior Visit 1 Requirement concomitant treatment prohibit medication History intolerance hypersensitivity drug chemical class F17464 rescue medication history severe drug allergy hypersensitivity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Mental disorder</keyword>
	<keyword>Antipsychotic Drugs</keyword>
</DOC>